Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Mark on +44 1494 818 049 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Mark Denton
Managing Director
+44 1494 818 049

I would highly recommend the service of Zenopa. It remained very professional throughout and aided me in getting my current position with Covidien.
Gareth, 2011

Almirall and Forest announce positive COPD trial results

7 January 2010 00:00 in Pharmaceutical Company Product News

Almirall and Forest Laboratories have announced that a phase III trial that compared the chronic obstructive pulmonary disease (COPD) therapy aclidinium bromide BID with a placebo has yielded positive results.

In a statement, the companies explained that the study met its primary endpoint of having aclidinium bromide producing statistically significant changes from baseline in the morning pre-dose trough FEV versus the placebo after three months.

Commenting on the news, Per-Olof Andersson, executive director of research and development at Almirall, said that the firm is "encouraged" by the fruitful top-line results.

The results are consistent with earlier research which compared aclidinium with tiotropium and a placebo.

Lawrence Olanoff, president and chief operating officer of Forest Laboratories, added: "These data suggest that aclidinium administered BID provides a clinically-important bronchodilatory effect with good tolerability in patients with COPD."

This news follows Alimirall's recent announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for its silodosin drug.

Other news stories from 07/01/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd